Annexure- F
BROAD PRAMETERS PERTAINING TO FUND FLOW
MECHANISM AND FINANCIAL PROCEDURES FOR ADOPTION BY FDAs.
(a)
The funds received by the FDA from NAEB shall be deposited in their
exclusive and separate current account in a Nationalised Bank, which would be
operated jointly by its Chairperson and the Member Secretary.
(b)
The FDA shall release the amount earmarked for all JFMCs/ EDCs by
demand draft within 15 days of receipt of funds from the NAEB, MoEF based on
the fund requirement, progress of implementation and utilisation of earlier
releases.
(c)
The respective JFMCs/ EDCs shall deposit the funds thus received from
the FDA in their exclusive and separate account in a Nationalised Bank/ a
Cooperative Bank or a Post Office, which would be singly operated by its Member
Secretary, i.e., the concerned Forest Block Forest Officer/ Forester.
(d)
Each JFMC/ EDC shall submit a quarterly statement of accounts and
progress of works carried out by them to the FDA.
(e)
The FDA shall submit a comprehensive annual report on the progress of
works and utilisation of funds in respect of all JFMCs/ EDCs to the respective
State Forest Department and the NAEB, MoEF. However, these details have to be
furnished by the FDA each time they seek for release of the next instalmement
of funds under the project.
(f)
The Project shall be implemented in the areas as indicated in the
project proposal and approved by the NAEB, MoEF.
(g)
The interest amount accrued on the deposits of these funds shall be
treated as part of the FDA’s additional resources and would be adjusted towards
further instalments of the grant.
(h)
The funds released under the scheme shall be subject to audit by the
Comptroller and Auditor General of
(i)
The FDA shall be responsible for guidance, coordination, supervision,
periodical reporting and monitoring the implementation of the project by their
constituent JFMCs/ EDCs.
(j)
The project shall be monitored periodically by the respective State
Forest Department and the officials of NAEB, MoEF and all assistance for this
purpose will be rendered by the FDA.
(k)
The project should be completed within the approved project period.
The FDA shall furnish 2 copies of detailed report through the PCCF to NAEB as
per the format prescribed by NAEB within two months of completion of the
project.
(l)
NAEB reserve the right to terminate the grant at any stage if it is
convinced that the grant has not been properly utilised or appropriate progress
has not been made.
(m)
In case the FDA fails to
execute the project within the stipulated time, including such extensions as
may be granted by NAEB, NAEB may, in its discretion, require the FDA to refund
the grant in whole or in such part along with interest thereon as NAEB may
specify.
(n)
There will be no diversion of funds from one JFMC/ EDC to another save
in exceptional circumstances and with the prior approval of NAEB.
(o)
The FDA will submit non-diversion and non-embezzlement certificate
each time a request for release of grant is made to NAEB.
(p)
The auditing of accounts of the FDA will have to be carried out
through a reputed Charted Accountant who is also on the panel of C&AG.
(q)
The FDA also submit a certificate to the effect that all conditions
laid down in the guidelines and the sanction order are being followed each time
a request for release of grant is made to NAEB.
(r)
FDA/ JFMCs will maintain a record of all assets created under the
project as per GFR 151.
(s)
Contractors / middlemen/ intermediate agencies are not permitted to be
engaged for execution of any of the works under the scheme so that full benefit of wages to be paid reach the workers.
(t)
Except for supervening impossibilities, the Chairperson and the Member
Secretary of the FDA shall be solely responsible and accountable for successful
implementation of the project.
********